Thomas D. Schmittgen PhD

Thomas D. Schmittgen PhD
ProfessorCollege of Pharmacyschmittgen.2@osu.edu
536 Parks Hall 500 W 12th Avenue Columbus Ohio 43210
Phone:614-292-3456Fax: 614-292-7766
  • Experimental Therapeutics

Current Publications

  • Elgamal OA, Park JK, Gusev Y, Azevedo-Pouly AC, Jiang J, Roopra A, Schmittgen TDTumor Suppressive Function of mir-205 in Breast Cancer Is Linked to HMGB3 Regulation.PLoS One 8(10) e76402 10/2/2013
  • Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM, Bloomston MA Differential MicroRNA Profile Distinguishes Cholangiocarcinoma from Pancreatic Adenocarcinoma.Ann Surg Oncol in press 9/18/2013
  • Schmittgen TDMicrobiomarkers with big impact in CLL.Blood 122(11) 1843-4 9/12/2013
  • McNally ME, Collins A, Wojcik SE, Liu J, Henry JC, Jiang J, Schmittgen T, Bloomston MConcomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma.HPB (Oxford) 15(4) 260-4 4/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu